Orange County Newsroom

August 21, 2026

Experts debated CAR T-cell therapies and bispecific antibodies for multiple myeloma in a 'Face-Off' event. Discussions focused on efficacy, safety and real-world factors from trials like CARTITUDE-4 (CAR T-cell) and MajesTEC-3 (bispecific antibodies). City of Hope's Amrita Y. Krishnan, M.D., emphasized that rapidly progressing disease and patient support are key considerations when selecting between therapies. The teams also compared accessibility, quality of life and toxicity management strategies for advanced immune-based treatments.

August 21, 2026

City of Hope's Irene M. Kang, M.D. and Sara Nunnery, M.D., discussed new first-line treatments for metastatic triple-negative breast cancer (mTNBC) using TROP2-directed antibody-drug conjugates (ADCs). The discussion centered on sacituzumab govitecan-hziy and datopotamab deruxtecan-dlnk, particularly for patients ineligible for immunotherapy. Kang explained TNBC’s historical management difficulties and the benefits of ADCs as targeted chemotherapy. They also compared the efficacy and distinct toxicity profiles of these agents, highlighting recent FDA approvals.